BioCryst Pharmaceuticals, Inc.: Business Overview, Financials & Competitive Analysis

BioCryst Pharmaceuticals, Inc. Overview

BioCryst Pharmaceuticals is a global biotechnology company focused on improving the lives of people living with complement-mediated and other rare diseases, leveraging structure-guided drug design to develop oral small-molecule and protein therapeutics. The company has commercialized ORLADEYO (berotralstat), the first oral, once-daily plasma kallikrein inhibitor, and is advancing a pipeline of small-molecule and protein therapies.

Strategic Profile

BioCryst delivered full-year ORLADEYO revenue of $601.8 million, representing 38% year-over-year growth, with aggressive expansion in the hereditary angioedema market bolstered by the recent acquisition of Astria Therapeutics and FDA approval of ORLADEYO pellets for young children. The company is positioning itself to own the entire prophylactic treatment decision framework for HAE patients by offering daily oral capsules for adults, oral pellets for children, and the long-acting Navenibart injectable for severe cases.

Competitive Landscape

BioCryst is aggressively positioning itself to own the entire prophylactic treatment decision framework for HAE patients through a multi-asset strategy offering daily oral capsules for adults, oral pellets for children, and the long-acting Navenibart injectable for severe cases. The company faces competition in the broader rare disease and complement-mediated disease space from other biotech and pharma companies.

Industry Context

BioCryst Pharmaceuticals, Inc. operates in Biotechnology - Rare Disease Therapeutics.

Key facts

Founded: 1986 · Headquarters: Durham, North Carolina, US · Revenue: $601M (2025)